[Therapeutic recommendations for migraine].
Géraud
Gilles
G
Service de neurologie, Hôpital de Rangueil, Toulouse.
D000700:Analgesics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000150:complications / Q000453:epidemiology; D001676:Biofeedback, Psychology; D015897:Comorbidity; D003866:Depressive Disorder / Q000150:complications / Q000453:epidemiology; D016903:Drug Monitoring; D004878:Ergotamine / Q000627:therapeutic use; D005602:France / Q000453:epidemiology; D006801:Humans; D008881:Migraine Disorders / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012064:Relaxation Therapy; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan; D004878:Ergotamine